Gracell Biotechnologies Key Executives
This section highlights Gracell Biotechnologies's key executives, including their titles and compensation details.
Find Contacts at Gracell Biotechnologies
(Showing 0 of )
Gracell Biotechnologies Earnings
This section highlights Gracell Biotechnologies's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|---|---|---|---|---|
| Read Transcript | Q3 | 2023 | 2023-11-13 | $-0.26 | $-0.10 |
| Read Transcript | Q2 | 2023 | 2023-08-14 | $-0.37 | $-0.30 |
| Read Transcript | Q1 | 2023 | 2023-05-15 | $-0.35 | $-0.35 |
Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People's Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate that is in Phase I trial for the treatment of multiple myeloma; GC019F, a FasTCAR-enabled CD19-directed autologous CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult B cell acute lymphoblastic leukemia (B-ALL), as well as in preclinical stage for the treatment of relapsed or refractory (r/r) B cell non-Hodgkin's lymphoma (B-NHL); and GC027, a TruUCAR-enabled CD7-directed allogeneic CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult T cell acute lymphoblastic leukemia. The company's product candidates also comprise GC007g, a donor-derived CD19-directed allogeneic CAR-T cell therapy that is in Phase 1/2 registrational trial clinical trial for the treatment of r/r B-ALL; and GC502, a TruUCAR-enabled dual CD19- and CD7 -directed, off-the-shelf allogeneic CAR-T product candidate, which is in Phase I trial for the treatment of B-cell malignancies. In addition, it has a portfolio of earlier stage product candidates targeting various cancer indications, such as ovarian cancer, breast cancer, peripheral T cell lymphoma, a subtype of NHL, and T cell lymphoblastic leukemia. The company was founded in 2017 and is headquartered in Suzhou, China.
$10.25
Stock Price
$989.87M
Market Cap
314
Employees
Suzhou, None
Location
Financial Statements
Access annual & quarterly financial statements for Gracell Biotechnologies, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2022 | December 31, 2021 | December 31, 2020 | December 31, 2019 | December 31, 2018 |
|---|---|---|---|---|---|
| Revenue | $- | $366.00K | $- | $- | $- |
| Cost of Revenue | $- | $- | $- | $- | $- |
| Gross Profit | $- | $366.00K | $- | $- | $- |
| Gross Profit Ratio | 0.00% | 100.00% | 0.00% | 0.00% | 0.00% |
| Research and Development Expenses | $485.39M | $326.90M | $168.83M | $119.22M | $52.24M |
| General and Administrative Expenses | $139.27M | $137.04M | $45.57M | $27.36M | $10.26M |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $139.27M | $137.04M | $45.57M | $27.36M | $10.26M |
| Other Expenses | $8.16M | $9.06M | $4.70M | $1.43M | $276.00K |
| Operating Expenses | $624.66M | $463.94M | $214.40M | $146.58M | $62.50M |
| Cost and Expenses | $624.66M | $463.94M | $214.40M | $146.58M | $62.50M |
| Interest Income | $23.92M | $9.12M | $2.87M | $3.93M | $1.44M |
| Interest Expense | $6.74M | $5.06M | $2.15M | $- | $- |
| Depreciation and Amortization | $32.08M | $78.45M | $7.57M | $2.57M | $2.99M |
| EBITDA | $-592.58M | $-385.13M | $-206.83M | $-144.01M | $-57.80M |
| EBITDA Ratio | 0.00% | -105225.96% | 0.00% | 0.00% | 0.00% |
| Operating Income | $-624.66M | $-463.57M | $-214.40M | $-146.58M | $-62.50M |
| Operating Income Ratio | 0.00% | -126659.29% | 0.00% | 0.00% | 0.00% |
| Total Other Income Expenses Net | $17.17M | $11.82M | $2.50M | $7.92M | $1.71M |
| Income Before Tax | $-607.49M | $-451.75M | $-211.90M | $-138.66M | $-60.79M |
| Income Before Tax Ratio | 0.00% | -123430.05% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | $22.00K | $14.13M | $-14.74M | $-6.49M | $1.71M |
| Net Income | $-607.51M | $-465.88M | $-197.16M | $-132.18M | $-60.79M |
| Net Income Ratio | 0.00% | -127289.62% | 0.00% | 0.00% | 0.00% |
| EPS | $-5.65 | $-7.08 | $-3.01 | $-6.67 | $-3.07 |
| EPS Diluted | $-5.65 | $-7.08 | $-3.01 | $-6.67 | $-3.07 |
| Weighted Average Shares Outstanding | 107.49M | 65.77M | 65.56M | 19.81M | 19.81M |
| Weighted Average Shares Outstanding Diluted | 107.49M | 65.77M | 65.56M | 19.81M | 19.81M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 | December 31, 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $- | $- | $- | $- | $- | $- | $- | $- | $366.00K | $- | $- | $- | $- | $- | $- | $- |
| Cost of Revenue | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Gross Profit | $- | $- | $- | $- | $- | $- | $- | $- | $366.00K | $- | $- | $- | $- | $- | $- | $- |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research and Development Expenses | $90.05M | $103.80M | $137.51M | $113.14M | $133.35M | $117.06M | $121.84M | $107.58M | $88.62M | $65.27M | $65.43M | $60.69M | $39.99M | $40.80M | $27.36M | $37.97M |
| General and Administrative Expenses | $31.70M | $37.35M | $29.09M | $36.18M | $36.43M | $28.77M | $37.89M | $32.00M | $42.86M | $30.42M | $31.76M | $24.79M | $8.18M | $6.97M | $5.62M | $7.92M |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $31.70M | $37.35M | $29.09M | $36.18M | $36.43M | $28.77M | $37.89M | $32.00M | $42.86M | $30.42M | $31.76M | $24.79M | $8.18M | $6.97M | $5.62M | $7.92M |
| Other Expenses | $2.40M | $1.68M | $630.00K | $3.99M | $2.23M | $1.80M | $144.00K | $8.25M | $733.00K | $-48.00K | $128.00K | $2.91M | $223.00K | $1.57M | $-10.00K | $1.22M |
| Operating Expenses | $121.75M | $141.15M | $166.59M | $149.32M | $169.78M | $145.82M | $159.73M | $139.58M | $131.48M | $95.69M | $97.19M | $85.48M | $48.17M | $47.77M | $32.98M | $45.89M |
| Cost and Expenses | $121.75M | $141.15M | $166.59M | $149.32M | $169.78M | $145.82M | $159.73M | $139.58M | $131.48M | $95.69M | $97.19M | $85.48M | $48.17M | $47.77M | $32.98M | $45.89M |
| Interest Income | $9.91M | $5.27M | $14.63M | $15.14M | $3.58M | $2.70M | $2.50M | $3.46M | $2.98M | $1.73M | $932.00K | $454.00K | $250.00K | $1.00M | $1.16M | $1.44M |
| Interest Expense | $1.29M | $1.70M | $1.66M | $1.79M | $1.86M | $1.66M | $1.43M | $1.33M | $1.09M | $1.41M | $1.24M | $805.00K | $654.00K | $490.00K | $206.00K | $- |
| Depreciation and Amortization | $12.31M | $6.95M | $15.26M | $19.13M | $5.81M | $4.50M | $2.64M | $12.32M | $3.72M | $1.69M | $1.06M | $9.35M | $473.00K | $2.57M | $1.15M | $1.32M |
| EBITDA | $-109.45M | $-134.20M | $-151.34M | $-130.20M | $-163.97M | $-141.32M | $-157.09M | $-127.86M | $-127.39M | $-94.00M | $-96.13M | $-72.76M | $-47.70M | $-45.20M | $-31.83M | $-49.83M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -34807.10% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | $-121.75M | $-141.15M | $-166.59M | $-149.32M | $-169.78M | $-145.82M | $-159.73M | $-139.58M | $-131.11M | $-95.69M | $-97.19M | $-85.48M | $-48.17M | $-47.77M | $-32.98M | $-45.89M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -35822.95% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income Expenses Net | $54.14M | $-5.77M | $14.88M | $18.65M | $-2.14M | $-481.00K | $1.14M | $10.99M | $1.83M | $-529.00K | $-473.00K | $1.89M | $-2.40M | $1.98M | $1.03M | $3.09M |
| Income Before Tax | $-67.61M | $-146.92M | $-151.71M | $-130.67M | $-171.93M | $-146.31M | $-158.58M | $-128.59M | $-129.28M | $-96.22M | $-97.67M | $-83.59M | $-50.57M | $-45.78M | $-31.95M | $-42.80M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -35323.77% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | $13.00K | $10.00K | $16.00K | $22.00K | $279.00K | $-1.18M | $-2.57M | $-12.32M | $-1.90M | $-322.00K | $303.00K | $-5.63M | $404.00K | $-513.00K | $-957.00K | $-6.70M |
| Net Income | $-67.62M | $-146.93M | $-151.73M | $-130.69M | $-172.21M | $-145.13M | $-156.01M | $-128.59M | $-129.28M | $-96.22M | $-97.67M | $-83.59M | $-50.57M | $-45.78M | $-31.95M | $-42.80M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -35323.77% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | $-0.81 | $-2.15 | $-2.24 | $-1.93 | $-2.54 | $-2.14 | $-2.31 | $-1.95 | $-1.92 | $-1.43 | $-1.60 | $-1.37 | $-0.77 | $-2.31 | $-1.61 | $-2.16 |
| EPS Diluted | $-0.81 | $-2.15 | $-2.24 | $-1.93 | $-2.54 | $-2.14 | $-2.31 | $-1.95 | $-1.92 | $-1.43 | $-1.60 | $-1.37 | $-0.77 | $-2.31 | $-1.61 | $-2.16 |
| Weighted Average Shares Outstanding | 83.92M | 68.13M | 67.71M | 67.69M | 67.68M | 67.67M | 67.63M | 65.77M | 67.30M | 67.23M | 60.90M | 60.90M | 65.56M | 19.81M | 19.81M | 19.81M |
| Weighted Average Shares Outstanding Diluted | 83.92M | 68.27M | 67.71M | 67.69M | 67.68M | 67.67M | 67.63M | 65.77M | 67.30M | 67.23M | 60.90M | 60.90M | 65.56M | 19.81M | 19.81M | 19.81M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2022 | December 31, 2021 | December 31, 2020 | December 31, 2019 | December 31, 2018 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $1.45B | $1.83B | $754.31M | $312.06M | $11.89M |
| Short Term Investments | $3.56M | $3.62M | $18.74M | $4.20M | $102.00M |
| Cash and Short Term Investments | $1.46B | $1.83B | $773.05M | $316.26M | $113.89M |
| Net Receivables | $- | $0 | $- | $- | $- |
| Inventory | $-26.33M | $8.70M | $-30.96M | $9.39M | $7.70M |
| Other Current Assets | $37.55M | $46.04M | $42.42M | $20.14M | $10.89M |
| Total Current Assets | $1.50B | $1.89B | $815.47M | $340.35M | $127.96M |
| Property Plant Equipment Net | $144.67M | $173.44M | $119.08M | $71.86M | $20.56M |
| Goodwill | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- |
| Long Term Investments | $- | $- | $- | $- | $- |
| Tax Assets | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $15.85M | $1.62M | $30.40M | $- | $- |
| Total Non-Current Assets | $160.52M | $175.06M | $149.48M | $71.86M | $20.56M |
| Other Assets | $- | $-0 | $- | $- | $- |
| Total Assets | $1.66B | $2.06B | $964.95M | $412.22M | $148.52M |
| Account Payables | $- | $62.46M | $- | $- | $- |
| Short Term Debt | $129.99M | $86.00M | $50.96M | $- | $- |
| Tax Payables | $- | $- | $- | $- | $- |
| Deferred Revenue | $2.90M | $2.90M | $- | $- | $- |
| Other Current Liabilities | $90.65M | $3.76M | $42.40M | $18.17M | $7.44M |
| Total Current Liabilities | $220.64M | $155.12M | $93.36M | $18.17M | $7.44M |
| Long Term Debt | $52.99M | $69.18M | $51.93M | $138.69M | $138.69M |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $6.88M | $8.46M | $- | $- | $- |
| Total Non-Current Liabilities | $59.87M | $77.64M | $51.93M | $138.69M | $138.69M |
| Other Liabilities | $- | $- | $- | $- | $- |
| Total Liabilities | $280.51M | $232.77M | $145.29M | $156.86M | $146.13M |
| Preferred Stock | $- | $- | $1.41B | $547.84M | $83.40M |
| Common Stock | $223.00K | $223.00K | $68.00K | $68.00K | $69.00K |
| Retained Earnings | $-1.63B | $-1.02B | $-564.03M | $-289.40M | $-81.09M |
| Accumulated Other Comprehensive Income Loss | $73.53M | $-57.94M | $-23.91M | $-3.16M | $- |
| Other Total Stockholders Equity | $2.93B | $2.84B | $- | $- | $- |
| Total Stockholders Equity | $1.38B | $1.83B | $819.66M | $255.36M | $2.38M |
| Total Equity | $1.38B | $1.83B | $819.66M | $255.36M | $2.38M |
| Total Liabilities and Stockholders Equity | $1.66B | $2.06B | $964.95M | $412.22M | $148.52M |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $1.66B | $2.06B | $964.95M | $412.22M | $148.52M |
| Total Investments | $3.56M | $3.62M | $18.74M | $4.20M | $102.00M |
| Total Debt | $182.98M | $155.18M | $102.89M | $138.69M | $138.69M |
| Net Debt | $-1.27B | $-1.67B | $-651.42M | $-173.36M | $126.81M |
Balance Sheet Charts
| Breakdown | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | December 31, 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $1.68B | $-157.98M | $1.27B | $1.45B | $1.43B | $1.54B | $1.62B | $1.83B | $1.95B | $2.05B | $2.16B | $754.31M | $156.78M | $312.06M |
| Short Term Investments | $30.46M | $3.57M | $3.57M | $3.56M | $198.16M | $172.20M | $73.58M | $3.62M | $3.60M | $3.73M | $11.61M | $18.74M | $20.70M | $4.20M |
| Cash and Short Term Investments | $1.71B | $1.19B | $1.28B | $1.46B | $1.63B | $1.71B | $1.69B | $1.83B | $1.96B | $2.05B | $2.17B | $773.05M | $177.48M | $316.26M |
| Net Receivables | $- | $- | $- | $- | $- | $- | $- | $0 | $- | $- | $- | $30.96M | $- | $- |
| Inventory | $- | $1.70K | $- | $-26.33M | $- | $21.55M | $- | $8.70M | $- | $- | $- | $6.62M | $8.00M | $9.39M |
| Other Current Assets | $66.40M | $53.70M | $47.53M | $37.55M | $40.34M | $24.17M | $66.60M | $46.04M | $60.93M | $62.94M | $54.90M | $42.42M | $34.06M | $20.14M |
| Total Current Assets | $1.77B | $1.25B | $1.32B | $1.50B | $1.67B | $1.74B | $1.76B | $1.89B | $2.02B | $2.12B | $2.22B | $815.47M | $215.70M | $340.35M |
| Property Plant Equipment Net | $108.67M | $119.59M | $137.06M | $144.67M | $149.91M | $156.70M | $144.08M | $173.44M | $156.15M | $161.68M | $143.81M | $119.08M | $124.92M | $71.86M |
| Goodwill | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Long Term Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Tax Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $7.04M | $10.89M | $11.76M | $15.85M | $18.51M | $3.17M | $27.86M | $1.62M | $22.24M | $13.53M | $19.90M | $30.40M | $- | $- |
| Total Non-Current Assets | $115.70M | $130.48M | $148.82M | $160.52M | $168.42M | $159.87M | $171.94M | $175.06M | $178.39M | $175.21M | $163.71M | $149.48M | $124.92M | $71.86M |
| Other Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Assets | $1.89B | $1.38B | $1.47B | $1.66B | $1.84B | $1.90B | $1.93B | $2.06B | $2.20B | $2.29B | $2.39B | $964.95M | $340.62M | $412.22M |
| Account Payables | $- | $- | $- | $- | $- | $- | $- | $62.46M | $- | $- | $- | $- | $- | $- |
| Short Term Debt | $80.45M | $115.48M | $136.53M | $129.99M | $146.80M | $121.56M | $104.97M | $86.00M | $75.97M | $76.25M | $77.11M | $50.96M | $20.24M | $- |
| Tax Payables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Revenue | $- | $- | $- | $2.90M | $- | $2.90M | $- | $2.90M | $- | $- | $- | $- | $- | $- |
| Other Current Liabilities | $149.02M | $78.34M | $75.07M | $90.65M | $99.74M | $92.64M | $82.15M | $6.66M | $61.31M | $55.62M | $43.91M | $42.40M | $11.95M | $18.17M |
| Total Current Liabilities | $229.48M | $193.82M | $211.60M | $220.64M | $246.54M | $217.10M | $187.12M | $155.12M | $137.28M | $131.87M | $121.02M | $93.36M | $32.19M | $18.17M |
| Long Term Debt | $35.37M | $42.50M | $46.09M | $52.99M | $56.98M | $60.51M | $65.92M | $69.18M | $74.44M | $76.93M | $61.52M | $51.93M | $44.64M | $138.69M |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $4.02M | $4.85M | $5.38M | $6.88M | $7.91M | $7.76M | $7.68M | $8.46M | $9.44M | $10.10M | $11.08M | $- | $- | $- |
| Total Non-Current Liabilities | $39.39M | $47.35M | $51.47M | $59.87M | $64.89M | $68.27M | $73.59M | $77.64M | $83.88M | $87.04M | $72.60M | $51.93M | $44.64M | $138.69M |
| Other Liabilities | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities | $268.86M | $241.17M | $263.07M | $280.51M | $311.43M | $285.38M | $260.72M | $232.77M | $221.16M | $218.91M | $193.62M | $145.29M | $76.83M | $156.86M |
| Preferred Stock | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $1.41B | $- | $547.84M |
| Common Stock | $324.00K | $225.00K | $223.00K | $223.00K | $223.00K | $223.00K | $223.00K | $223.00K | $223.00K | $222.00K | $222.00K | $68.00K | $144.00K | $68.00K |
| Retained Earnings | $-1.99B | $-1.92B | $-1.78B | $-1.63B | $-1.49B | $-1.32B | $-1.18B | $-1.02B | $-889.19M | $-759.90M | $-663.68M | $-564.03M | $-464.10M | $-289.40M |
| Accumulated Other Comprehensive Income Loss | $113.94M | $118.09M | $55.65M | $73.53M | $98.71M | $17.66M | $-64.37M | $-57.94M | $-27.71M | $-35.05M | $-284.00K | $-23.91M | $-5.12M | $-3.16M |
| Other Total Stockholders Equity | $3.50B | $3.06B | $2.99B | $2.93B | $3.02B | $2.94B | $2.85B | $2.84B | $2.86B | $2.87B | $2.86B | $- | $-5.12M | $- |
| Total Stockholders Equity | $1.62B | $1.14B | $1.21B | $1.38B | $1.53B | $1.61B | $1.67B | $1.83B | $1.98B | $2.07B | $2.19B | $819.66M | $263.79M | $255.36M |
| Total Equity | $1.62B | $1.14B | $1.21B | $1.38B | $1.53B | $1.61B | $1.67B | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Stockholders Equity | $1.89B | $1.38B | $1.47B | $1.66B | $1.84B | $1.90B | $1.93B | $2.06B | $2.20B | $2.29B | $2.39B | $964.95M | $340.62M | $412.22M |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $1.89B | $1.38B | $1.47B | $1.66B | $1.84B | $1.90B | $1.93B | $2.06B | $2.20B | $2.29B | $2.39B | $964.95M | $340.62M | $412.22M |
| Total Investments | $30.46M | $3.57M | $3.57M | $3.56M | $198.16M | $172.20M | $73.58M | $3.62M | $3.60M | $3.73M | $11.61M | $18.74M | $20.70M | $4.20M |
| Total Debt | $115.82M | $157.98M | $182.62M | $182.98M | $203.78M | $182.07M | $170.89M | $155.18M | $150.42M | $153.19M | $138.63M | $102.89M | $64.88M | $138.69M |
| Net Debt | $-1.56B | $315.95M | $-1.09B | $-1.27B | $-1.23B | $-1.35B | $-1.45B | $-1.67B | $-1.80B | $-1.90B | $-2.02B | $-651.42M | $-91.90M | $-173.36M |
Annual Cash Flow
| Breakdown | December 31, 2022 | December 31, 2021 | December 31, 2020 | December 31, 2019 | December 31, 2018 |
|---|---|---|---|---|---|
| Net Income | $-4.16B | $-451.75M | $-211.90M | $-138.66M | $-60.79M |
| Depreciation and Amortization | $531.08M | $60.27M | $21.59M | $5.12M | $2.99M |
| Deferred Income Tax | $- | $- | $- | $- | $- |
| Stock Based Compensation | $165.15M | $60.38M | $- | $- | $- |
| Change in Working Capital | $103.34M | $25.26M | $-10.75M | $703.00K | $-4.05M |
| Accounts Receivables | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- |
| Accounts Payables | $- | $- | $- | $- | $- |
| Other Working Capital | $- | $- | $- | $- | $- |
| Other Non Cash Items | $55.97M | $1.30M | $2.91M | $-2.56M | $- |
| Net Cash Provided by Operating Activities | $-3.31B | $-304.55M | $-198.15M | $-135.39M | $-61.86M |
| Investments in Property Plant and Equipment | $-331.55M | $-56.74M | $-79.40M | $-56.43M | $-11.36M |
| Acquisitions Net | $1.79B | $10.00M | $28.05M | $-97.80K | $- |
| Purchases of Investments | $-1.79B | $-10.00M | $-28.05M | $-80.20M | $-335.00M |
| Sales Maturities of Investments | $1.79B | $25.13M | $13.51M | $178.00M | $233.00M |
| Other Investing Activities | $-1.79B | $-10.00M | $-28.05M | $97.80K | $- |
| Net Cash Used for Investing Activities | $-331.17M | $-41.62M | $-93.94M | $41.37M | $-113.36M |
| Debt Repayment | $- | $- | $- | $- | $- |
| Common Stock Issued | $- | $1.45B | $- | $- | $- |
| Common Stock Repurchased | $- | $- | $- | $-44.70M | $- |
| Dividends Paid | $- | $- | $- | $- | $- |
| Other Financing Activities | $228.34M | $1.46B | $756.47M | $394.80M | $138.69M |
| Net Cash Used Provided by Financing Activities | $228.34M | $1.46B | $756.47M | $394.80M | $138.69M |
| Effect of Forex Changes on Cash | $844.82M | $-35.32M | $-22.13M | $-603.00K | $- |
| Net Change in Cash | $-2.57B | $1.07B | $442.25M | $300.17M | $-36.52M |
| Cash at End of Period | $9.97B | $1.83B | $754.31M | $312.06M | $11.89M |
| Cash at Beginning of Period | $12.53B | $754.31M | $312.06M | $11.89M | $48.41M |
| Operating Cash Flow | $-3.31B | $-304.55M | $-198.15M | $-135.39M | $-61.86M |
| Capital Expenditure | $-331.55M | $-56.74M | $-79.40M | $-56.43M | $-11.36M |
| Free Cash Flow | $-3.64B | $-361.29M | $-277.55M | $-191.82M | $-73.21M |
Cash Flow Charts
| Breakdown | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | December 31, 2020 | December 31, 2019 |
|---|---|---|---|---|---|---|---|
| Net Income | $-68.15M | $-151.60M | $-152.44M | $-125.84M | $-179.16M | $-83.59M | $-42.80M |
| Depreciation and Amortization | $- | $- | $- | $- | $- | $9.35M | $1.32M |
| Deferred Income Tax | $- | $- | $- | $- | $- | $- | $- |
| Stock Based Compensation | $- | $- | $- | $- | $- | $- | $- |
| Change in Working Capital | $- | $- | $- | $- | $- | $9.61M | $9.13M |
| Accounts Receivables | $- | $- | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- | $- | $- |
| Accounts Payables | $- | $- | $- | $- | $- | $- | $- |
| Other Working Capital | $- | $- | $- | $- | $- | $- | $- |
| Other Non Cash Items | $68.15M | $151.60M | $152.44M | $125.84M | $179.16M | $677.00K | $-429.00K |
| Net Cash Provided by Operating Activities | $- | $- | $- | $- | $- | $-63.95M | $-32.78M |
| Investments in Property Plant and Equipment | $- | $- | $- | $- | $- | $-14.11M | $-10.24M |
| Acquisitions Net | $- | $- | $- | $- | $- | $- | $- |
| Purchases of Investments | $- | $- | $- | $- | $- | $45.65M | $-71.12M |
| Sales Maturities of Investments | $- | $- | $- | $- | $- | $-43.69M | $80.00M |
| Other Investing Activities | $- | $- | $- | $- | $- | $- | $- |
| Net Cash Used for Investing Activities | $- | $- | $- | $- | $- | $-12.15M | $-1.36M |
| Debt Repayment | $- | $- | $- | $- | $- | $- | $- |
| Common Stock Issued | $- | $- | $- | $- | $- | $- | $- |
| Common Stock Repurchased | $- | $- | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $- | $- | $- | $- | $- | $693.13M | $- |
| Net Cash Used Provided by Financing Activities | $- | $- | $- | $- | $- | $693.13M | $- |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $- | $-19.50M | $-3.77M |
| Net Change in Cash | $486.41M | $-161.48M | $-164.30M | $50.61M | $-196.05M | $597.53M | $-37.92M |
| Cash at End of Period | $1.68B | $1.18B | $1.27B | $1.43B | $1.44B | $754.31M | $312.06M |
| Cash at Beginning of Period | $1.19B | $1.34B | $1.44B | $1.38B | $1.64B | $156.78M | $349.97M |
| Operating Cash Flow | $- | $- | $- | $- | $- | $-63.95M | $-32.78M |
| Capital Expenditure | $- | $- | $- | $- | $- | $-14.11M | $-10.24M |
| Free Cash Flow | $- | $- | $- | $- | $- | $-78.06M | $-43.02M |
Gracell Biotechnologies Dividends
Explore Gracell Biotechnologies's dividend history, including dividend yield, payout ratio, and historical payments.
Gracell Biotechnologies News
Read the latest news about Gracell Biotechnologies, including recent articles, headlines, and updates.
Gracell Biotechnologies Acquisition Completed
SAN DIEGO and SUZHOU, China and SHANGHAI, China, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (“Gracell” or the “Company”, Nasdaq: GRCL), a global clinical-stage biopharmaceutical company developing innovative cell therapies for the treatment of cancer and autoimmune disease, today announced the completion of its previously announced agreement to be acquired by AstraZeneca, in accordance with the terms and conditions of the Agreement and Plan of Merger, dated as of December 23, 2023 (the “Merger Agreement”), by and among the Company, AstraZeneca Treasury Limited, a private limited company incorporated under the laws of England and Wales (“Parent”), and Grey Wolf Merger Sub (“Merger Sub”), an exempted company with limited liability incorporated under the laws of the Cayman Islands and a wholly owned subsidiary of Parent. The acquisition was structured as a merger of Merger Sub with and into the Company with the Company surviving the merger as a wholly owned subsidiary of Parent (the “Merger”). As a result of the Merger, the Company ceased to be a publicly traded company and became a wholly owned subsidiary of Parent.
Gracell Biotechnologies Announces Shareholders' Approval of Merger Agreement
SAN DIEGO and SUZHOU, China and SHANGHAI, China, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (“Gracell” or the “Company”, NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing innovative and highly efficacious cell therapies for the treatment of cancer and autoimmune disease, today announced that at an extraordinary general meeting of shareholders (the “EGM”) held on February 19, 2024, the Company's shareholders voted in favor of the proposal to approve and authorize the execution, delivery and performance by the Company of the previously announced Agreement and Plan of Merger, dated as of December 23, 2023 (the “Merger Agreement”), by and among the Company, AstraZeneca Treasury Limited, a private limited company incorporated under the laws of England and Wales (“Parent”), and Grey Wolf Merger Sub, an exempted company with limited liability incorporated under the laws of the Cayman Islands and a wholly owned subsidiary of Parent (“Merger Sub”), the Plan of Merger required to be filed with the Registrar of Companies of the Cayman Islands (the “Plan of Merger”), and the other agreements or documents contemplated by the Merger Agreement or any document or instrument delivered in connection thereunder (the “Transaction Documents”) to which the Company is a party and the consummation of the transactions contemplated by the Merger Agreement (including the Merger) and the Contingent Value Rights Agreement, in the form attached as Exhibit B to the Merger Agreement, (collectively, the “Transactions”), upon the terms and subject to the conditions set forth therein. Pursuant to the Merger Agreement, in accordance with the applicable provisions of the Companies Act (As Revised) of the Cayman Islands, Merger Sub will merge with and into the Company at the effective time of the Merger, with the Company continuing as the surviving company and becoming a wholly owned subsidiary of the Parent (the “Merger”).
Gracell Biotechnologies Announces FDA Clearance of IND Application for Phase 1 Clinical Trial of FasTCAR-T GC012F as Early-Line Treatment of Multiple Myeloma
Further expands clinical development of FasTCAR-T GC012F in multiple myeloma amid ongoing U.S. trial evaluating therapy for treatment of relapsed/refractory multiple myeloma Further expands clinical development of FasTCAR-T GC012F in multiple myeloma amid ongoing U.S. trial evaluating therapy for treatment of relapsed/refractory multiple myeloma
GRACELL BIOTECHNOLOGIES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Gracell Biotechnologies Inc. - GRCL
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Gracell Biotechnologies Inc. (NasdaqGS: GRCL) to AstraZeneca. Under the terms of the proposed transaction, shareholders of Gracell will receive $2.00 per ordinary share in cash at closing (equivalent to $10.00 per ADS of Gracell), plus a non-tradable contingent value right of $0.30 per ordinary share in cash (.
GRCL Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Gracell Biotechnologies Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Gracell Biotechnologies Inc. (NASDAQ: GRCL) to AstraZeneca is fair to Gracell shareholders. Under the terms of the proposed transaction, AstraZeneca will acquire Gracell for $2.00 per ordinary share in cash at closing (equivalent to $10.00 per ADS of Gracell), plus a non-tradable contingent value right of $0.30 per ordinary share in cash (equivalent to $1.50 per ADS of Gracell) payable.
AstraZeneca to acquire Gracell, furthering cell therapy ambition across oncology and autoimmune diseases
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca has entered into a definitive agreement to acquire Gracell Biotechnologies Inc. (Gracell, NASDAQ: GRCL), a global clinical-stage biopharmaceutical company developing innovative cell therapies for the treatment of cancer and autoimmune diseases, furthering the AstraZeneca cell therapy ambition. The proposed acquisition will enrich AstraZeneca's growing pipeline of cell therapies with GC012F, a novel, clinical-stage FasTCAR-enabled BCMA and CD19 dual.
Gracell Biotechnologies to be acquired by AstraZeneca, furthering cell therapy ambition across oncology and autoimmune diseases
Proposed acquisition will enrich the AstraZeneca cell therapy pipeline with clinical-stage autologous BCMA/CD19 CAR-T therapy targeting haematologic malignancies and autoimmune diseases, and proprietary cell therapy manufacturing platform Gracell shareholders to receive $2.00 per ordinary share (equivalent to $10.00 per American Depositary Share (ADS)) in cash at closing, plus a non-tradable contingent value right (CVR) for up to $0.30 per ordinary share (equivalent to $1.50 per ADS), representing a total transaction value of up to $1.2 billion including the CVR SAN DIEGO and SUZHOU, China and SHANGHAI, China, Dec. 26, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (“Gracell” or the “Company”, NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing innovative cell therapies for the treatment of cancer and autoimmune diseases, today announced it has entered into a definitive agreement to be acquired by AstraZeneca. The proposed acquisition will enrich AstraZeneca's growing pipeline of cell therapies with GC012F, a novel, clinical-stage FasTCAR-enabled BCMA and CD19 dual-targeting autologous chimeric antigen receptor T (CAR-T) cell therapy, a potential new treatment for multiple myeloma, as well as other haematologic malignancies and autoimmune diseases including systemic lupus erythematosus (SLE).
Gracell Biotechnologies Inc. Sponsored ADR (GRCL) Is a Great Choice for 'Trend' Investors, Here's Why
Gracell Biotechnologies Inc. Sponsored ADR (GRCL) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Gracell Biotechnologies Announces China NMPA Clearance for IND Application for Phase 1/2 Clinical Trial of FasTCAR-T GC012F for the Treatment of Refractory Systemic Lupus Erythematosus
Expands clinical development of GC012F in rSLE following FDA IND clearance for Phase 1/2 trial in the United States Gracell is pioneering use of a CD19/BCMA dual-targeted CAR-T cell therapy in rSLE, aiming for deeper and wider depletion of disease-causing antibody secreting cells and B-cells FasTCAR-T GC012F has demonstrated a favorable safety profile in clinical investigator-initiated trials in 60 patients with multiple myeloma and B-cell non-Hodgkin lymphoma SAN DIEGO and SUZHOU, China and SHANGHAI, China, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (“Gracell” or the “Company”, NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing innovative and highly efficacious cell therapies for the treatment of cancer and autoimmune disease, today announced that the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has cleared Gracell's Investigational New Drug (IND) application for GC012F, an autologous CAR-T therapeutic candidate, for the treatment of refractory systemic lupus erythematosus (rSLE). Under the IND, Gracell plans to initiate a Phase 1/2 clinical study in China to further evaluate GC012F in rSLE patients.
Gracell Biotechnologies Presents Updated Clinical Data from FasTCAR-T GC012F Demonstrating Deep and Durable Responses in Newly Diagnosed Multiple Myeloma at ASH 2023
Minimal residual disease negativity (MRD-) observed in all treated patients in the ongoing study, with 95% (21/22) achieving stringent complete response (sCR) through a median follow-up of 18.8 months
Wall Street Analysts Believe Gracell Biotechnologies Inc. Sponsored ADR (GRCL) Could Rally 127.82%: Here's is How to Trade
The mean of analysts' price targets for Gracell Biotechnologies Inc. Sponsored ADR (GRCL) points to a 127.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Gracell Biotechnologies Announces FDA Clearance of IND Application for Phase 1/2 Clinical Trial of FasTCAR-T GC012F for the Treatment of Refractory Systemic Lupus Erythematosus
Gracell is pioneering use of a CD19/BCMA dual-targeted CAR-T cell therapy in refractory systemic lupus erythematosus, aiming for deeper and wider depletion of disease-causing antibody secreting cells and B-cells
Does Gracell Biotechnologies Inc. Sponsored ADR (GRCL) Have the Potential to Rally 120.94% as Wall Street Analysts Expect?
The consensus price target hints at a 120.9% upside potential for Gracell Biotechnologies Inc. Sponsored ADR (GRCL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Gracell Biotechnologies Inc. (GRCL) Q3 2023 Earnings Call Transcript
Gracell Biotechnologies Inc. (NASDAQ:GRCL ) Q3 2023 Earnings Conference Call November 13, 2023 8:00 AM ET Company Participants William Cao - Chairman and CEO Wendy Li - Chief Medical Officer Kevin Xie - CFO Conference Call Participants Yigal Nochomovitz - Citi Benjamin Burnett - Stifel Dev Prasad - Jefferies Eric Schmidt - Cantor Emily Bodnar - H.C. Wainwright Yanan Zhu - Wells Fargo Securities Joseph Catanzaro - Piper Sandler Justin Zelin - BTIG Operator Ladies and gentlemen, thank you for standing by.
Gracell Biotechnologies Reports Third Quarter 2023 Unaudited Financial Results and Provides Corporate Update
SAN DIEGO, Calif. and SUZHOU and SHANGHAI, China, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell” or the “Company”), a global clinical-stage biopharmaceutical company dedicated to developing innovative and highly efficacious cell therapies for the treatment of cancer and autoimmune diseases, today reported third quarter unaudited financial results for the period ended September 30, 2023, and provided corporate updates.
Gracell Biotechnologies to Present Updated Results from BCMA/CD19 Dual-Targeting FasTCAR-T GC012F in Newly Diagnosed Multiple Myeloma at the 65ᵗʰ American Society of Hematology Annual Meeting & Exposition
Oral presentation of the updated results from ongoing Phase 1 investigator-initiated study of GC012F in frontline setting for transplant-eligible, high-risk newly diagnosed multiple myeloma
Gracell Biotechnologies to Participate in Four Upcoming Investor Conferences
SAN DIEGO and SUZHOU, China and SHANGHAI, China, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing innovative and highly efficacious cell therapies for the treatment of cancer and autoimmune disease, today announced that the management team will participate in four upcoming investor conferences in November. Stifel 2023 Healthcare Conference Fireside Chat: Tuesday, November 14th at 1:15 pm ETOne-on-one meetings: November 14th, 2023Presenter: Dr. Kevin Xie, Chief Financial OfficerLocation: New York Jefferies London Healthcare Conference Fireside Chat: Wednesday, November 15th at 11:30 am GMT / 6:30 am ETOne-on-one meetings: November 15th and 16th, 2023Presenter: Dr. Kevin Xie, Chief Financial OfficerLocation: London Piper Sandler 35 th Annual Healthcare Conference Presentation: Tuesday, November 28th at 12:00 pmOne-on-one meetings: November 28th, 2023Presenter: Dr. Kevin Xie, Chief Financial OfficerLocation: New York 6th Annual Evercore ISI HealthCONx Conference Presentation: Wednesday, November 29th at 9:35 am ETOne-on-one meetings: November 29th and 30th, 2023Presenter: Dr. Kevin Xie, Chief Financial OfficerLocation: Miami Available webcasts of the presentations will be posted on the News and Events section of the Company's website.
Gracell Biotechnologies to Present Data Highlighting Preclinical Efficacy of SMART CART™ Against Solid Tumors at Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
Novel, proprietary technology designed to strengthen the functionality of CAR-T cells against solid tumors SMART CAR-T cells demonstrated resistance to immunosuppressive tumor microenvironment (TME) and maintained long-term proliferation and cytotoxicity both in vitro and in vivo Launching investigator-initiated trial (IIT) of SMART CART GC506 targeting Claudin 18.2 positive tumors SAN DIEGO and SUZHOU, China and SHANGHAI, China, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (“Gracell” or the “Company”, NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing innovative and highly efficacious cell therapies for the treatment of cancer and autoimmune disease, announced today preclinical data from the Company's SMART CART™* technology for solid tumors will be presented as a poster at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting, taking place November 1-5, 2023, in San Diego and online. “Gracell has long been dedicated to unlocking the tremendous potential of CAR-T therapy against solid tumors in our pursuit of transformative cell therapies.
Gracell Biotechnologies to Report Third Quarter 2023 Financials on Monday, November 13, 2023
SAN DIEGO and SUZHOU, China and SHANGHAI, China, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to developing innovative and highly efficacious cell therapies for the treatment of cancer and autoimmune diseases, today announced that it plans to release unaudited financial results for the third quarter ended September 30, 2023 and provide an update on recent developments prior to the open of the U.S. financial markets on Monday, November 13, 2023. The management team will host a live audio webcast and conference call at 8:00 AM Eastern Time.
Gracell Biotechnologies Reports Updated Clinical Data for FasTCAR-T GC012F for High-Risk, Newly Diagnosed Multiple Myeloma, Demonstrating 100% Stringent Complete Response Rate
SAN DIEGO and SUZHOU, China and SHANGHAI, China, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (“Gracell” or the “Company”, NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing innovative and highly efficacious cell therapies for the treatment of cancer and autoimmune disease, today presented longer-term follow-up data from an ongoing Phase 1 investigator-initiated trial (IIT) evaluating GC012F, a CD19 and B-cell maturation antigen (BCMA) dual-targeted autologous CAR-T therapeutic candidate, as a frontline treatment for patients with transplant-eligible, high-risk, newly diagnosed multiple myeloma (NDMM). The abstract (P-136) was presented as a poster at the 20th International Myeloma Society (IMS) Annual Meeting in Athens, Greece.
Gracell Biotechnologies Doses First Patient in Phase 1b/2 Clinical Trial in U.S. Evaluating GC012F for Treatment of Relapsed/Refractory Multiple Myeloma
SAN DIEGO and SUZHOU, China and SHANGHAI, China, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing innovative and highly efficacious cell therapies for the treatment of cancer and autoimmune disease, today announced that the first patient has been dosed in a Phase 1b/2 clinical trial evaluating its lead candidate, GC012F, in patients with relapsed or refractory multiple myeloma (RRMM) in the United States. GC012F is the Company's autologous therapeutic candidate dual-targeting B cell maturation antigen (BCMA) and CD19, developed on the proprietary FasTCAR next-day manufacturing platform.
Gracell Biotechnologies' CEO Dr. William Cao Named to Prestigious PharmaVoice 100, Honoring Most Inspiring Life Science Leaders
SAN DIEGO and SUZHOU, China and SHANGHAI, China, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing innovative and highly efficacious cell therapies for the treatment of cancer and autoimmune disease, today announced that its Founder, Chairman and Chief Executive Officer William (Wei) Cao, Ph.D., B.M., has been named to the PharmaVoice 100, a recognition of the most inspiring leaders in the life-sciences industry.
Gracell Biotechnologies to Participate in Three Upcoming Investor Conferences
SAN DIEGO and SUZHOU, China and SHANGHAI, China, Sept. 14, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to discovering and developing innovative and highly efficacious cell therapies for the treatment of cancer, today announced that the management team will participate in and attend one-on-one meetings at three upcoming investor conferences.
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for GRCL.